Variations in adiponectin levels in patients with chronic kidney disease: a prospective study of 12 months

Maria Ayako Kamimura1, Maria Eugênia Fernandes Canziani, Fabiana Ribeiro Sanches

  • 1Programa de Pós-Graduação em Nutrição, EPM, Universidade Federal de São Paulo.

Insights

In chronic kidney disease (CKD) patients, adiponectin levels are linked to age, sex, GFR, and visceral fat. Increased visceral fat over time independently predicts lower adiponectin levels.

Area of Science:

  • Nephrology
  • Endocrinology
  • Cardiology

Background:

  • Cardiovascular complications are a leading cause of mortality in chronic kidney disease (CKD).
  • Adiponectin, an adipose-derived protein, possesses cardioprotective properties.
  • Understanding adiponectin determinants in CKD is crucial for managing cardiovascular risk.

Purpose of the Study:

  • To investigate the factors influencing adiponectin levels in patients with chronic kidney disease.
  • To determine the relationship between adiponectin and clinical, biochemical, and body composition parameters in CKD.
  • To assess the longitudinal association between changes in body fat and adiponectin levels over 12 months.

Main Methods:

  • A prospective observational study involving 98 non-dialyzed CKD patients.
  • Baseline and 12-month assessments included adiponectin levels, glomerular filtration rate (GFR), proteinuria, body mass index (BMI), and abdominal fat (visceral and subcutaneous) via computed tomography.
  • Statistical analyses included correlation and linear regression to identify determinants of adiponectin.

Main Results:

  • Adiponectin levels correlated negatively with GFR, BMI, and visceral fat, and positively with proteinuria.
  • Independent predictors of adiponectin at baseline were female sex, age, GFR, and visceral fat.
  • Over 12 months, CKD progression was observed (decreased GFR, increased proteinuria), accompanied by increased visceral fat and a significant reduction in adiponectin levels.
  • Increased visceral fat independently predicted the decrease in adiponectin over time.

Conclusions:

  • Adiponectin levels in non-dialyzed CKD patients are independently associated with age, sex, renal function (GFR), and visceral fat.
  • Changes in visceral fat are the primary predictor of adiponectin level variations over a 12-month period in this population.
  • Targeting visceral fat may be a strategy to modulate adiponectin levels and potentially mitigate cardiovascular risk in CKD.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...